© 2020 MJH Life Sciences and HCPLive. All rights reserved.
© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.
June 19, 2019
Both brick-and-mortar dermatology clinics as well as telehealth programs are limited and restricted by barriers to access.
June 17, 2019
Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.
The new approval allows for easier access to MRIs and direct audio streaming from Android devices.
In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.